Foresite Capital is an equity investment firm with a strong focus on the healthcare industry. The company provides operating capital to biotech startups to enable them to deliver innovative value that enhances patient care. Jim Tananbaum is the founder and CEO of Foresite Capital. Recently the company engaged a renowned scientific researcher, Dr. Molly He, to become a venture partner at the firm. Dr. He has over fifteen year’s research experience in pharmaceuticals and genome sequencing. Check out LinkedIn Forsite Capital
Welcoming Dr. He to the Foresite stable, Jim Tananbaum expressed confidence in her outstanding leadership. Foresite Capital was established in 2011 and is headquartered in San Francisco with an office in New York. It continues to invest in transformational biotech and pharmaceutical companies with futuristic products. The company is setting the pace in investments in biotechnology, pharmaceutical, and medical research.
Jim Tananbaum is an experienced venture capitalist. He has vast interests in over twenty healthcare companies. Some of the business he is associated with include Amerigroup, Healtheon, Amira and Jazz Pharmaceuticals among others. He is also a founding partner of several active venture capital groups such as Prospect Venture Partners I through III. He has previously held key management positions with companies such as Theravance, Sierra Ventures, and Pathwork Diagnostics.
Jim attended Yale University where he graduated with a science degree. He went to Harvard University for his medical doctor’s degree. Jim went to Harvard Business School and obtained a master’s in business administration. Additionally, he received a master’s degree from the Massachusetts Institute of Technology. Visit LinkedIn to know more.
Jim Tananbaum recently made the Forbes Midas List of top one hundred “best venture investors.” This is the third consecutive year he has received the honor. The award honors bold investment moves in futuristic biotech companies that deliver value to investors.
Dr. Tananbaum is adept at identifying strategic opportunities and driving the capital required to grow them. Through Foresite Capital, Jim Tananbaum is currently involved in several biotech companies such as Aimmune, Puma Biotechnology, and Juno Therapeutics. One of his flagship projects is Intarcia Therapeutics, a privately held Boston biotech company.
Jim Tananbaum has been instrumental in shaping Foresite Capital’s investment footprint. He has been involved in the leadership of various companies the group has funded guiding the organization structure and venture policy. More details can be found on his Crunchbase and Facebook page.